Comparison of autologous peripheral blood stem cell dosing by ideal vs actual body weight

Bone Marrow Transplantation

Volumn 23, Issue 9, 1999, Pages 867-873

  Waples, J M ^a   Moreb, J S ^a,c   Sugrue, M ^a   Belanger, G ^a   Kubilis, P ^b   Lynch, J W ^a   Gian, V ^a   Weeks, F ^a   Wingard, J ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c Division of Hematology/Oncology   (United States)

Author keywords

Actual body weight; Autologous stem cell transplantation; Cell dose; Ideal body weight

Indexed keywords

CARBOPLATIN; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; THIOTEPA;

ADULT; APHERESIS; ARTICLE; BODY WEIGHT; BREAST CANCER; COLONY FORMING UNIT GM; COST CONTROL; FEMALE; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; STEM CELL TRANSPLANTATION; THROMBOCYTE;

EID: 0032962188     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701731     Document Type: Article

References (33)

1. Weaver CH, Hazelton B, Birch R et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995; 86: 3961-3969.
2. Glaspy JA, Shpall EJ, LeMaistre CF et al. Peripheral blood progenitor cell mobilization using stem cell factor in combination with filgrastim in breast cancer patients. Blood 1997; 90: 2939-2951.
3. Schmitz N, Linch DC, Dreger P et al. Randomized trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone marrow transplantation in lymphoma patients. Lancet 1996; 347: 353-357.
4. Beyer J, Schwella N, Zingsem J et al. Hematopoietic rescue after high-dose chemotherapy using autologous peripheral blood progenitor cells on bone marrow: a randomized comparison. J Clin Oncol 1995; 13: 1328-1335.
5. Damiani D, Fanin R, Silvestri F et al. Randomized trial of autologous filgrastim-primed bone marrow transplantation versus filgrastim-mobilized peripheral blood stem cell transplantation with lymphoma patients. Blood 1997; 90: 36-42.
6. Janssen WE, Smilee RC, Elfenbein GJ. A prospective randomized trial comparing blood- and marrow-derived stem cells for hematopoietic replacement following high-dose chemotherapy. J Hematother 1995; 4: 139-140.
7. Reiffers J, Faberes C, Boiron JM et al. Peripheral blood progenitor cell transplantation in 118 patients with hematological malignancies: analysis of factors affecting the rate of engraftment. J Hematother 1994; 3: 185-191.
8. Rowley S, Zuehldsorf M, Braine HG et al. CFU-GM content of bone marrow graft correlates with time to hematologic reconstitution following autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide-purged bone marrow. Blood 1987; 70: 271-275.
9. Douay L, Gorin NC, Mary JY et al. Recovery of CFU-GM from cryopreserved marrow and in vivo evaluation after autologous bone marrow transplantation are predictive of engraftment. Exp Hematol 1986; 14: 358-365.
10. Shea TC, Mason JR, Breslin M et al. Reinfusion and serial measurements of carboplatin-mobilized peripheral blood progenitor cells in patients receiving multiple cycles of high-dose chemotherapy. J Clin Oncol 1994; 12: 1012-1020.
11. Nademanee A, Sniecinski I, Schmidt GM et al. High dose therapy followed by autologous peripheral blood stem cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor mobilized peripheral blood stem cells. J Clin Oncol 1994; 12: 2176-2186.
12. Bensinger W, Appelbaum FR, Rowley S et al. Factors that influence collection and engraftment of autologous peripheral blood stem cells. J Clin Oncol 1995; 13: 2547-2555.
13. Haas R, Mohle R, Fruhauf S et al. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994; 83: 3787-3794.
14. Tricot G, Jagannath S, Vesole D et al. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood 1995; 85: 588-596.
15. Watts MJ, Sullivan AM, Jamieson E et al. Progenitor cell mobilization after low dose cyclophosphamide and granulocyte colony-stimulating factor: an analysis of progenitor cell quantity and quality and factors predicting for these parameters in 101 pretreated patients with malignant lymphoma. J Clin Oncol 1997; 15: 535-546.
16. Bolwell BJ, Fishleder A, Andresen SW et al. G-CSF primed peripheral blood progenitor cells in autologous bone marrow transplantation: parameters affecting bone marrow engraftment. Bone Marrow Transplant 1993; 12: 609-614.
17. Zimmerman TM, Lee WJ, Bender JG et al. Quantitative CD34 analysis may be used to guide peripheral blood stem cell harvests. Bone Marrow Transplant 1995; 9: 439-444.
18. + cells after stem cell mobilization predict stem cell yield and post-transplant hematopoietic recovery. J Hematother 1997; 6: 13-19.
19. Passos-Coelho JL, Braine HG, Davis JM et al. Predictive factors for peripheral blood progenitor cell collections using a single large-volume leukapheresis after cyclophosphamide and granulocyte-macrophage colony-stimulating factor mobilization. J Clin Oncol 1991; 13: 705-714.
20. Bensinger WI, Longin K, Appelbaum FR et al. Peripheral blood stem cells (PBPCs) collected after recombinant granulocyte colony stimulating factor (rhG-CSF): an analysis of factors correlating with the tempo of engraftment after transplantation. Br J Haematol 1994; 87: 825-831.
21. Siena S, Bregni M, Brando B et al. Flow cytometry for clinical estimation of circulating hematopietic progenitors for autologous transplantation in cancer patients. Blood 1991; 77: 400-409.
22. + versus colony-forming cell in bone marrow and mobilized peripheral blood stem cell harvests. Blood 1997; 90: 336b (Abstr. 4263).
23. -) hematopoietic progenitor mobilization following chemotherapy and/or cytokine priming. Blood 1996; 88: 678a, (Abstr. 2702).
24. + cells. Bone Marrow Transplant 1998; 21: 983-985.
25. Stroncek D, Clay M, Smith J et al. Composition of peripheral blood progenitor cell components collected from healthy donors. Transfusion 1997; 37:411-417.
26. Holm M, Hokland P. Not all healthy donors mobilize hematopoietic progenitor cells sufficiently after G-CSF administration to allow for subsequent CD34 purification of the leukapheresis product. J Hematother 1998; 7: 111-113.
27. Grigg A, Roberts A, Raunow H et al. Optimizing dose and scheduling of filgrastim (granulocyte colony-stimulating factor) for mobilization and collection of peripheral blood progenitor cells in normal volunteers. Blood 1995; 86: 4437-4445.
28. Tabilio A, Falzetti F, Giannoni C et al. Stem cell mobilization in normal donors. J Hematother 1997; 6: 227-234.
29. Devine DJ. Gentamicin therapy. Drug Intell Clin Pharm 1974; 8: 650-655.
30. Sharp JG, Kessinger A, Mann S et al. Detection and clinical significance of minimal tumor cell contamination of peripheral blood stem cell harvests. Int J Cell Clon 1992; 10: 92.
31. Sharp JG, Kessinger A, Mann S et al. Outcome of high dose therapy and autologous transplantation in non-Hodgkin's lymphoma based on the presence of tumor in the marrow or infused hematopoietic harvest. J Clin Oncol 1996; 14: 214-219.
32. Shpall EJ, Jones RB. Release of tumor cells from bone marrow. Blood 1994; 83: 623-625.
33. Barlogie B, Jagannath S, Vesole DH et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997; 89: 789-793.